CIDP and membranous nephropathy: a case with limited electrophysiological findings and a rare association

Baslo, Sezin Alpaydın; İdrisoğlu, Halil Atilla; Aral, Orhan; Öge, Ali Emre

doi:10.1007/s10072-020-04612-1

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several previous reports have described the association of CIDP with nephropathy. [6][7][8][15][16][17][18][19][20][21][22][25][26][27][28][29][30][31][32][33] In recent years, a variety of autoantibodies directing against the nodes/paranodes, including neurofascin 155 (NF155), contactin-1 (CNTN1), contactin-associated protein 1 (Caspr1), and neurofascin 186 (NF186) have been identified. Atay Vural et al 11 defined seropositive CIDP as patients with antibodies against neurofascin, CNTN1 and Caspr1 and suggested these subgroups of patients had unique characteristics that distinguished them from patients with seronegative CIDP.…”

Section: Discussionmentioning

confidence: 99%

“…Several previous reports have described the association of CIDP with nephropathy. 6 , 7 , 8 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 In recent years, a variety of autoantibodies directing against the nodes/paranodes, including neurofascin 155 (NF155), contactin‐1 (CNTN1), contactin‐associated protein 1 (Caspr1), and neurofascin 186 (NF186) have been identified. Atay Vural et al.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

CIDP/autoimmune nodopathies with nephropathy: a case series study

Tang

Liu

Gao

et al. 2023

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Objective: The co-morbidity of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)/autoimmune nodopathies with nephropathy has been gradually known in recent years. This study was intended to explore the clinical, serological and neuropathological features of seven patients with CIDP/ autoimmune nodopathies and nephropathy. Methods: Among 83 CIDP patients, seven were identified with nephropathy. Their clinical, electrophysiological and laboratory examination data were collected. The nodal/paranodal antibodies were tested. The sural biopsies were performed in all the patients, and renal biopsies were operated in 6 patients. Results: Six patients had chronic onsets and one had an acute onset. Four patients exhibited peripheral neuropathy preceding nephropathy while two showed concurrent onset of neuropathy and nephropathy, and one started with nephropathy. All the patients showed demyelination in electrophysiological examination. Nerve biopsies showed mild to moderate mixed neuropathies including demyelinating and axonal changes in all patients. Renal biopsies showed membranous nephropathy in all 6 patients. Immunotherapy was effective in all patients, with two patients showing good response to corticosteroid treatment alone. Four of the patients were positive to anti-CNTN1 antibody. Compared with anti-CNTN1 antibodynegative patients, antibody-positive patients had a higher proportion of ataxia (3/4 vs. 1/3), autonomic dysfunction (3/4 vs. 1/3), less frequent antecedent infections (1/4 vs. 2/3), higher cerebrospinal fluid proteins (3.2 g/L vs. 1.69 g/ L), more frequent conduction block on electrophysiological examination (3/4 vs. 1/3), higher myelinated nerve fiber density, and positive CNTN1 expression in the glomeruli of kidney tissues. Conclusion: Anti-CNTN1 antibody was the most frequent antibody in this group of patients with CIDP/autoimmune nodopathies and nephropathy. Our study suggested that there might be some clinical and pathological differences between the antibody positive and negative patients.

show abstract